CCR6 and rheumatoid arthritis: Previous reports have stated that, in a mouse model of rheumatoid arthritis, the addition of anti-CCR6 monoclonal antibodies inhibited the trafficking of Th17 cells to the arthritic joint and impeded early disease development [10].